NCT02278601

Brief Summary

Epidural analgesia is the gold standard of pain relief for labour pain. Despite this, more than 50% of parturients continue to experience pain leading to suffering and increased caregiver workload. Women who have increased pain tend to have lower successful patient bolus demands when patient controlled epidural analgesia (PCEA) is utilised and have dysfunctional labour requiring obstetric intervention such as Caesarean or instrumental delivery. Labour pain often escalates and worsens as labour progresses requiring an individualized, variable, flexible analgesic regimen. Bolus epidural administrations have been shown to improve uniform spread of local anaesthetics with better pain relief, compared to fixed background infusions.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
839

participants targeted

Target at P75+ for phase_3

Timeline
8mo left

Started Jan 2015

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress95%
Jan 2015Dec 2026

First Submitted

Initial submission to the registry

October 26, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 30, 2014

Completed
3 months until next milestone

Study Start

First participant enrolled

January 28, 2015

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 6, 2019

Completed
7.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Expected
Last Updated

October 9, 2024

Status Verified

October 1, 2024

Enrollment Period

4.3 years

First QC Date

October 26, 2014

Last Update Submit

October 8, 2024

Conditions

Keywords

Breakthrough pain

Outcome Measures

Primary Outcomes (1)

  • Number of subjects with Breakthrough pain

    Unscheduled epidural supplementation by anaesthetist due to pain

    1 day

Secondary Outcomes (8)

  • Number of subjects with Caesarean section

    1 day

  • Number of subjects with Instrumental delivery

    1 day

  • Foetal outcome

    1 day

  • Willingness to pay

    1 day

  • Factors associated with epidural decisions

    1 day

  • +3 more secondary outcomes

Study Arms (3)

MPIB modified programmed intermittent bolus

EXPERIMENTAL

Modified programmed intermittent bolus (MPIB) up-down frequency of 5mls ropivacaine/fentanyl solution in bolus with epidural delivery system

Device: epidural delivery systemDrug: RopivacaineDrug: Fentanyl

CIPCEA

EXPERIMENTAL

computer integrated patient controlled epidural analgesia (CIPCEA) up-down variable basal infusion of ropivacaine/fentanyl solution with epidural delivery system

Device: epidural delivery systemDrug: RopivacaineDrug: Fentanyl

patient controlled epidural analgesia with basal infusion

ACTIVE COMPARATOR

patient controlled epidural analgesia (PCEA) with fixed basal infusion of ropivacaine/fentanyl solution with epidural delivery system

Device: epidural delivery systemDrug: RopivacaineDrug: Fentanyl

Interventions

epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution

CIPCEAMPIB modified programmed intermittent boluspatient controlled epidural analgesia with basal infusion

epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution

Also known as: amide local anaesthetic
CIPCEAMPIB modified programmed intermittent boluspatient controlled epidural analgesia with basal infusion

epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution

Also known as: opioid
CIPCEAMPIB modified programmed intermittent boluspatient controlled epidural analgesia with basal infusion

Eligibility Criteria

Age21 Years - 50 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy (ASA physical status 1 and 2) nulliparous parturients at term (≥36 weeks gestation);
  • Singleton foetus
  • Early labour (cervical dilation ≤5cm)
  • Request labour epidural analgesia
  • At least 21 years of age

You may not qualify if:

  • parturients with multiple pregnancies
  • non-cephalic foetal presentation
  • obstetric (e.g. pre-eclampsia, premature rupture of amniotic membranes, gestational diabetes on insulin) and uncontrolled medical (e.g. cardiac disease) complications
  • have contraindications to neuraxial blockade or have received parenteral opioids with the last 2 hours.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

KK Women's and Children's Hospital

Singapore, 229899, Singapore

Location

Related Publications (1)

  • Tan DJA, Lew JP, Jumhasan MB, Pang C, Sultana R, Sng BL. Investigating factors associated with success of breastfeeding in first-time mothers undergoing epidural analgesia: a prospective cohort study. Int Breastfeed J. 2018 Sep 5;13:42. doi: 10.1186/s13006-018-0184-7. eCollection 2018.

MeSH Terms

Conditions

Breakthrough Pain

Interventions

RopivacaineFentanylAnalgesics, Opioid

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsNarcoticsCentral Nervous System DepressantsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesAnalgesicsSensory System AgentsPeripheral Nervous System AgentsCentral Nervous System AgentsTherapeutic Uses

Study Officials

  • Ban L Sng, FANZCA

    KK Women's and Children's Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 26, 2014

First Posted

October 30, 2014

Study Start

January 28, 2015

Primary Completion

May 6, 2019

Study Completion (Estimated)

December 31, 2026

Last Updated

October 9, 2024

Record last verified: 2024-10

Locations